New Study Shows People with Type 2 Diabetes Benefit from Continuous Glucose Monitoring

August 21, 2017 The results show that continuous glucose monitoring is an effective diabetes management tool that could benefit millions of people with Type 2 diabetes on insulin therapy SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM), announced today the publication of a new study that shows people with Type 2 diabetes on a multiple daily injection (MDI) insulin therapy benefit from the use of continuous glucose monitoring (CGM). Participants in the study achieved significant A1C reduction and spent more time in range, regardless of age, education or math ability. The findings are the result of the DIaMonD study (Multiple Daily Injections and Continuous Glucose Monitoring in Diabetes), which assessed the impact of CGM on glycemic control in individuals with Type 2 diabetes on MDI insulin therapy. Results from a parallel arm of the study using participants with Type 1 diabetes were published in January 2017. "This study represents a significant step forward for the diabetes community," said Roy Beck, MD, lead study investigator from the Jaeb Center for Health Research. "The results allow us to confidently tell people with Type 2 diabetes using insulin they can use CGM to take control of their disease and make better treatment decisions." Published today in the Annals of Internal Medicine, the study showed: After 24 weeks participants with Type 2 diabetes using CGM while on MDI insulin therapy averaged a 0.8 percent A1C reduction compared to baseline (changes in A1C are measured as absolute percent changes; in this case, a reduction from an average baseline A1C of 8.5% to 7.7%) A subset of this group with an A1C of 9.0 percent or higher saw an average 1.4 percent reduction from baseline at week 24 The CGM group also decreased time in hyperglycemia and increased time spent in the target range compared to the control group (use of only a standard meter to test glucose) The CGM group increased time in range by 1.3 hours compared to baseline, and 0.6 hours compared to the control group The A1C reductions occurred with minimal changes in insulin dosages or regimen, and nearly no additions of non-insulin diabetes medications The study also dispels the perception that people with diabetes on an MDI regimen would find CGM too complicated or a hassle to use. Subjects in the study demonstrated significant A1C reductions regardless of age, education level or math ability and showed high rates of adherence - 93 percent of participants were still using CGM six or more days per week at the end of the study. Participants also reported a high level of satisfaction and a relatively low level of perceived hassles. "We have been successful in driving innovation and adoption of CGM in the Type 1 diabetes community, but this arm of the DIaMonD study is one of the first to examine how well CGM works for people with Type 2 diabetes on MDI," said Kevin Sayer, president and CEO of Dexcom. "We are pleased to see a significant A1C reduction in this study, showing that the millions of people globally with Type 2 diabetes on MDI insulin therapy can benefit from CGM use." The DIaMonD Type 2 diabetes study was conducted between October 2014 and May 2016 at 25 endocrinology practices in North America using 158 adult subjects with Type 2 diabetes on MDI insulin therapy. Participants ranged in age from 35 to 79 years, with a mean age of 60 years. The protocol was designed to reflect common clinical practice, with follow-up visits at months one, three and six. The study used the Dexcom G4® PLATINUM CGM System, which uses the same software as the current Dexcom G5® Mobile CGM System. The prevalence of diabetes continues to rise in the U.S. and around the world. According to the 2017 National Diabetes Statistics Report by the Centers for Disease Control and Prevention (CDC), more than 30 million people in the U.S. have diabetes, with 23.8 percent of that population undiagnosed. Among children and adolescents age 10 to 19, there were an estimated 5,300 newly diagnosed cases of Type 2 diabetes in the U.S. annually from 2011 to 2012. With diabetes being the seventh leading cause of death in 2015, health care costs related to the disease are also on the rise. Average medical expenditures among people with diabetes are more than twice those of people without the disease. About DexCom, Inc . DexCom, Inc., headquartered in San Diego, CA, is dedicated to helping people better manage their diabetes by developing and marketing continuous glucose monitoring (CGM) products and tools for adult and pediatric patients. With exceptional performance, patient comfort and lifestyle flexibility at the heart of its technology, users have consistently ranked DexCom highest in customer satisfaction and loyalty. For more information, visit www.dexcom.com . View source version on businesswire.com : http://www.businesswire.com/news/home/20170821005740/en/ DexCom, Inc. Media Contact James McIntosh 619-884-2118 [email protected] or Investor Contact Steven Pacelli 858-200-0200 [email protected] Source: DexCom, Inc. News Provided by Acquire Media View All News Follow us IR Contacts Matt Carey Director, Investor Relations Joe Deltorchio Lead Investor Relations Manager (858) 200-0200 [email protected] Investor Email Alerts To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time. At DexCom, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance. By providing your email address below, you are providing consent to DexCom, Inc. to send you the requested Investor Email Alert updates. * Required Email Address * Investor Alert Options Investor Alert Options * News Quarterly Reports Annual Reports SEC Filings End of Day Stock Quote Events & Presentations Unsubscribe Email Alert Sign Up Confirmation 1. JAMA. 2017;317(4):371-378. 2. Welsh, J.B. et al (2019). "Accuracy, Utilization, and Effectiveness Comparisons of Different Continuous Glucose Monitoring Systems." Diabetes Technol Ther 21(3) Dexcom, Dexcom G6, Dexcom Share, and Dexcom CLARITY are registered trademarks of Dexcom, Inc. in the United States and/or other countries. *If your glucose alerts and readings from the G6 or G7 CGM Systems do not match symptoms or expectations or you’re taking over the recommended maximum dosage amount of 1000mg of acetaminophen every 6 hours, use a blood glucose meter to make diabetes treatment decisions. Privacy Policy Terms of Use © Q4 Inc. - All rights reserved Powered By Q4 Inc. 5.187.1.9 (opens in new window)

The release as fetched from its publisher. dexcom.com ↗